Dana Farber Cancer Institute – The Adult Survivorship Program team and Lymphoma Division at Dana-Farber Cancer Institute has created an evidence-based Hodgkin Lymphoma online educational resource website for Hodgkin Lymphoma survivors, loved ones, caregivers, and clinicians. We have designed this program to describe the different aspects of survivorship for Hodgkin Lymphoma patients, including cancer risks, care of your heart, healthy living, emotional well-being, family and relationships, and general tips. This website provides specific strategies to manage potential late and long-term effects from chemotherapy and/or radiation for Hodgkin Lymphoma and other related cancers.

Medpage Today –

The research was presented in October, 2022 at the International Symposium on Hodgkin Lymphoma and earlier, at the ASCO (American Society for Clinical Oncology) Annual Meeting in 2021. A common chemotherapy drug used to treat Hodgkin lymphoma conferred a significantly increased risk of breast cancer among women treated during adolescence and adulthood, a large retrospective study showed.

HemOnc today –

This article in HemOnc Today describes a recent study that evaluated the use of specific biomarkers, namely global longitudinal strain (GLS) and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) to identify childhood cancer survivors who may be at risk for cardiomyopathy. The study was done through the St. Jude Lifetime Cohort study.

Coping Magazine –

Sometimes, moving our bodies is the LAST thing we want to do. Cancer survivorship can be exhausting. Fatigue is one of the most common effects of cancer treatment. And, the more late effects begin to pile up, the more tired we become, and the more likely we are to succumb to the couch. But there are many, many reasons why we shouldn’t.

Even a small amount of exercise can have a significant impact. Just about everyone can benefit from a daily walk.

Journal of Clinical Oncology –

This research paper takes a look at the risk of breast cancer from doxorubicin exposure in female survivors of Hodgkin lymphoma who are between the ages of 15-50 years of age and five years post treatment. The period of treatment was between 1975 and 2008. The study was first presented in 2021 at the ASCO Annual Meeting.

Of note is that the authors found an increased risk of breast cancer in this cohort independent of whether or not radiation was also a part of the treatment protocol.

Cancer.net –

When thinking about cancer research, many people think of studies focused on evaluating new or better ways to treat the cancer itself. What may not come to mind is a type of research known as “survivorship research.”

Consultant 360 –

Men with breast cancer tend to have a worse prognosis than women, as they commonly have more advanced disease at diagnosis. While many practitioners utilize mammography screening for women, there is less awareness of recommendations regarding screening for men.

Healio –

Patients with cancer had a higher rate of acute MI when presenting to the ED with chest pain.

Oncology Times –

A Phase III trial has demonstrated that patients with advanced Stage III/IV classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

Healio –

The number of cancer survivors with self-reported functional limitations throughout the United States has more than doubled over the past 2 decades, according to data published in JAMA Oncology.